DarioHealth (NASDAQ:DRIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of DarioHealth (NASDAQ:DRIO) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other research analysts have also issued reports on the stock. Cowen restated a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Stifel Nicolaus set a $16.00 price target on shares of DarioHealth in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, DarioHealth has an average rating of “Hold” and an average price target of $32.00.

DarioHealth Stock Performance

DarioHealth stock opened at $12.44 on Friday. DarioHealth has a fifty-two week low of $5.93 and a fifty-two week high of $17.74. The company has a market capitalization of $84.09 million, a price-to-earnings ratio of -1.11 and a beta of 1.05. The stock has a fifty day moving average of $11.94 and a two-hundred day moving average of $12.04. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd raised its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the quarter. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 at the end of the most recent quarter. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.